Our Research

We integrate multi-omics, digital pathology, and liquid biopsy approaches to build a comprehensive view of tumor complexity.

Integrative Molecular Pathology and Cancer Evolution

At the Noh Lab, we study how genetic, spatial, and microenvironmental diversity drive tumor behavior and clinical outcomes. Our work bridges molecular biology, pathology, and data science to understand cancer as an evolving ecosystem.

We combine multi-omics profiling, spatial transcriptomics, AI-driven image analysis, and liquid biopsy to dissect the molecular architecture of tumors at unprecedented resolution. Our overarching goal is to translate these insights into molecular stratification frameworks that inform diagnosis, prognosis, and individualized treatment planning.

Core Research Themes

1. Spatial and Molecular Heterogeneity

We investigate how tumor subclones, immune cells, and stromal components organize within the tumor microenvironment. Using spatial transcriptomics and AI-based digital pathology, we map how spatial immune architecture and molecular subtype patterns define cancer evolution and influence patient outcomes.

2. Tumor Adaptation and Resistance

Our research explores the mechanisms through which tumors adapt to selective pressures from targeted therapy to immune checkpoint inhibition. By integrating multi-omics data, we uncover tumor-intrinsic signaling and stromal cues that enable therapy resistance and tumor persistence.

3. Multi-Omics Integration for Precision Oncology

We aim to establish comprehensive multi-omics models that integrate genomics, transcriptomics, and proteomics with digital imaging and circulating biomarkers. This holistic view allows us to identify predictive and prognostic markers that refine patient stratification and clinical decision-making.

4. Translational Molecular Pathology Platform

Our group develops and applies cutting-edge translational workflows, from patient-derived biobanking and high-throughput sequencing to computational analysis and digital tissue profiling. These efforts are closely integrated with clinical partners to ensure a seamless interface between bench discovery and patient care.

5. Circulating Tumor Cells for Therapy Monitoring

We investigate circulating tumor cells (CTCs) as dynamic biomarkers for disease monitoring in non-small cell lung cancer. By longitudinally quantifying CTCs at defined time points during therapy, we aim to correlate CTC dynamics with treatment response, progression, and clinical outcome.

Research Vision

Cancer is not a static disease but a dynamic system shaped by continuous interaction between tumor cells, their microenvironment, and therapy. By decoding these interactions at multiple molecular and spatial levels, Noh Lab seeks to redefine how tumors are classified, monitored, and treated, moving from descriptive pathology toward mechanistic and data-driven precision pathology.